HomeHealthBD Promotes Two Senior Executives to Segment Leadership Roles

BD Promotes Two Senior Executives to Segment Leadership Roles

Published on

<br /> BD Promotes Two Senior Executives to Segment Leadership Roles<br />

PR Newswire


  • Mike


    Garrison Named EVP and President, Medical segment

  • Rick


    Byrd Named EVP and President, Interventional segment



FRANKLIN LAKES, N.J.


,


Aug. 25, 2022


/PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles.


Michael (Mike) Garrison

has been named executive vice president (EVP) and president of the Medical segment, and

Richard (Rick) Byrd

has been named executive vice president (EVP) and president of the Interventional segment, both effective

Sept. 6

.

Garrison and Byrd will be responsible for the global operational, commercial and financial performance of the businesses that comprise their respective segments, including advancing the portfolio and innovation agenda aligned to the BD 2025 strategy. They will also be accountable for advancing the overall culture and high-performing talent landscape within their segments. They will be members of the BD Executive Leadership Team and report to

Tom Polen

, chairman, CEO and president of BD.

In addition, BD announced that

Simon Campion

will depart the company on

Sept. 9

for an executive role in the health care industry. Campion joined BD through the acquisition of Bard and led BD’s Interventional segment through the integration. He most recently served as president of the Medical segment.

“Mike and Rick are highly effective leaders who have demonstrated strategic and operational excellence in their nearly two decades at BD,” said

Tom Polen

, chairman, CEO and president of BD. “Their focus on driving growth and meaningful outcomes has been critical as we pursue our BD 2025 strategy, and they are well-rounded, seasoned leaders with a track record of developing strong teams that deliver impactful results. Their broad experiences across multiple BD businesses and segments position them well for their new roles as we advance our growth agenda and build BD’s future. I would also like to thank Simon for his many contributions over his 14 years with Bard and BD.”




Mike Garrison

, EVP and president, Medical segment

Garrison, 53, has served as worldwide president of BD Medication Management Solutions (MMS) since 2020, during which he advanced the innovation agenda including BD’s most recent acquisition of Parata Systems. Prior to that he was worldwide president of BD Surgery, where he helped integrate legacy Bard and BD product platforms into an integrated Surgery offering and developed growth strategies for Advanced Repair and Reconstruction. He has also served as vice president and general manager of Worldwide Infusion Systems in MMS and held multiple senior roles across different business units across the company including vice president of Research and Development (R&D) for BD’s Medication and Procedural Solutions business unit. Before joining BD in 2005, Garrison worked at Edwards Lifesciences and Roche Diagnostics.

Garrison earned a doctorate in Bioengineering from the

University of Washington

and Bachelor and Master of Science degrees in Biomedical and Electrical Engineering from

Duke University

.




Rick Byrd

, EVP and president, Interventional segment

Byrd, 55, has served as worldwide president of Medication Delivery Solutions (MDS), BD’s largest business unit, since 2019, during which he drove high-impact category innovation through BD’s “One-Stick Hospital Stay” vision, which is transforming the in-patient experience by eliminating unnecessary needlesticks and accelerating growth with the acquisition of Velano Vascular. Previously, he served as worldwide president of Preanalytical Systems in BD Life Sciences, and vice president and general manager within BD Medical, where he led three global, multi-billion-dollar growth businesses within MDS. He also served in a number of R&D roles focused on innovation, including vice president of worldwide R&D within BD Medical.

Byrd earned a master’s degree in Mechanical Engineering from

Stevens Institute of Technology

and a Bachelor of Science degree in Mechanical Engineering from

Virginia Tech.


About BD


BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit

bd.com

or connect with us on LinkedIn at

www.linkedin.com/company/bd1/

and Twitter

@BDandCo

.



Contacts:



Media

:



Investors

:


Troy Kirkpatrick


Francesca DeMartino


VP, Public Relations


SVP, Head of Investor Relations


858.617.2361


201.847.5743



[email protected]



[email protected]

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/bd-promotes-two-senior-executives-to-segment-leadership-roles-301612805.html

SOURCE BD (Becton, Dickinson and Company)

rt BD Promotes Two Senior Executives to Segment Leadership Roles

Featured image: © realcg

Disclaimer

Latest News

Aetna 2023 Medicare plans put money back in members’ pockets

Aetna 2023 Medicare plans put money back in...

European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Fezolinetant

European Medicines Agency Accepts Astellas' Marketing Authorization Application...

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- ...

Q&M Group awards 7 dentists with Performance Shares,12-year Service Agreements, and a Private Placement

Q&M Group awards 7 dentists with Performance Shares,12-year...

More like this

Numinus to Participate in the Cantor Neurology and Psychiatry Conference on October 6-7, 2022

VANCOUVER, BC, Sept. 29, 2022 - Numinus Wellness Inc. ("Numinus" or the "Company")(TSX:NUMI)(OTCQX:NUMIF), a mental...

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health

Illumina Unveils Revolutionary NovaSeq X Series to Rapidly...

AbbVie Highlights Robust Gastroenterology Portfolio with New Data in Crohn’s Disease and Ulcerative Colitis at the UEG Week 2022

AbbVie Highlights Robust Gastroenterology Portfolio with New Data...

Cosmos Health Enters into Letter of Intent for the Acquisition of ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.

CHICAGO, IL / ACCESSWIRE / September 28, 2022 / Cosmos Holdings d/b/a Cosmos Health,...

Moderna Creates New Executive Committee Role Ahead of New Product Launches

Juan Andres Appointed to President, Strategic Partnerships and Enterprise ExpansionJerh Collins Joins Moderna as...